Flagship record · Tirzepatide

Tirzepatide for Obesity Treatment and Diabetes Prevention.

human primaryhigh controlled human primaryprimary subject

Scientific attribution

The governed peptide appears as the explicit intervention or exposure.

PMID: 39536238
DOI: 10.1056/NEJMoa2410819
Sample size: 1032
Population / model: 1032 participants with obesity and prediabetes from SURMOUNT-1

Intervention / comparator

Tirzepatide 5, 10, or 15 mg once weekly for 176 weeks vs Placebo

Outcomes

Percent body-weight change
Progression to type 2 diabetes
Safety
Post-treatment diabetes incidence

Key findings

At 176 weeks, mean weight changes were -12.3%, -18.7%, and -19.7% with tirzepatide 5, 10, and 15 mg, respectively, versus -1.3% with placebo.
Type 2 diabetes was diagnosed in 1.3% of tirzepatide-treated participants versus 13.3% receiving placebo during treatment.
After 17 weeks off treatment, diabetes incidence was 2.4% versus 13.7%, respectively.
The most common non-COVID adverse events were gastrointestinal.

Review status

This research library contains structured AI-assisted scientific review. AI-assisted review is not accountable human scientific approval. Inclusion here does not constitute publication approval, clinical guidance, efficacy proof, or automatic promotion of a scientific conclusion.

Loading research intelligence

Preparing the structured Flagship evidence library.